Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)

References

• CorlessCFletcherJAHeinrichMABiology of gastrointestinal stromal tumorsJ Clin Oncol20042238143824
   Web of Science ®Google Scholar
• KirschRGaoZHRiddellRGastrointestinal stromal tumors: diagnostic challenges and practical approach to differential diagnosisAdv Anat Pathol20071426128517592256
   PubMed Web of Science ®Google Scholar
• HuemanMTSchulickRDManagement of gastrointestinal stromal tumorsSurg Clin NA200888599614
   Web of Science ®Google Scholar
• RubinBPHeinrichMCCorlessCLGastrointestinal stromal tumourLancet20073691731174117512858
   PubMed Web of Science ®Google Scholar
• AgaimyAWunschPHHofstaedterFMinute gastric schlerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutationsAm J Surg Pathol20073111312017197927
   PubMed Web of Science ®Google Scholar
• KawanowaKSakumaYSakuraiSHigh incidence of microscopic gastrointestinal stromal tumors in the stomachHuman Pathol2006371527153516996566
   PubMed Web of Science ®Google Scholar
• RautCPAshleySWHow I do it: management of gastrointestinal stromal tumorsJ Gastrointest Surg2008121592159918317848
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma, V.2.2007Available at: http://www.globalgist.org/docs/NCCN_guidelines.pdf (accessed March 5th, 2009).
   Google Scholar
• BlumMGBilimoriaKYWayneJDSurgical considerations for the management and resection of esophageal gastrointestinal tumorsAnn Thor Surg20078417171723
   PubMed Web of Science ®Google Scholar
• WayneJDBellRHJrLimited gastric resectionSurg Clin NA20058510091020
   Web of Science ®Google Scholar
• NovitskyYMKetcherKWSingRFLong-term outcomes of laparoscopic resection of gastrointestinal stromal tumorsAnn Surg200624373874516772777
   PubMed Web of Science ®Google Scholar
• ChoiSMKimMCJungGC GJLaparoscopic wedge resection for gastric GIST: long-term follow-up resultsEur J Surg Oncol20073344444717174060
   PubMed Web of Science ®Google Scholar
• NishimuraJNakajimaKOmoriTSurgical strategy for gastrointestinal stromal tumors: laparoscopic vs. open resectionSurg Endosc 205;191109111116021371
   PubMed Web of Science ®Google Scholar
• DeMatteoRPGoldJSSaranLTumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)Cancer200811260818076015
   PubMed Web of Science ®Google Scholar
• FletcherCDMBermanJJCorlessCDiagnosis of gastrointestinal stromal tumors: a consensus approachHuman Pathol20023345946512094370
   PubMed Web of Science ®Google Scholar
• BlankeCDCorlessCLState-of-the art therapy for gastrointestinal stromal tumorsCancer Invest20052327428015945512
   PubMed Web of Science ®Google Scholar
• DemetriGDvonMehrenMBlankeCDEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsN Engl J Med200234747248012181401
   PubMed Web of Science ®Google Scholar
• BenjaminRSRankinCFletcherCPhase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early resultsProceedings of the American Society for Clinical Oncology200322(abstract 3271).
   Google Scholar
• VerweijJCasaliPGZalcbergJProgression-free survival in gastrointestinal stromal tumors with high-dose imatinib; randomised trialLancet20043641127113415451219
   PubMed Web of Science ®Google Scholar
• DrukerBJLydonNBLessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemiaJ Clin Invest20001053710619854
   PubMed Web of Science ®Google Scholar
• DeMatteoRPAntonescuCRChadaramVAdjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the US Intergroup Phase II trial ACOSOG Z9000Proceedings of the American Society for Clinical Oncology20052316S9009
   Google Scholar
• DeMatteoRPOwzarKAntonescuCREfficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST)at high risk of recurrence: the US Intergroup phase II trial ACOSOG Z9000. [Abstract]American Society of Clinical Oncology 2008 Gastrointestinal Cancers SymposiumJanuary 25–27, 2008Orlando, FLA-82008
   Google Scholar
• DeMatteoRPOwzarKMakiRGAdjuvant imatinib mesylate increases recurrence-free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST):North American Intergroup Phase III trial ACOSOG Z9001Proceedings of the American Society for Clinical Oncology 2007Abstract 10079.
   Google Scholar
• BonvalotSEldwenyHPechouxCLImpact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib mesylate eraAnn Surg Oncol2006131596160316957966
   PubMed Web of Science ®Google Scholar
• EisenbergBLHarrisJBlankeCDPhase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665J Surg Oncol20081021(Epub ahead of print)
   Web of Science ®Google Scholar
• DemetriGDBenjaminRSBlankeCDNCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelinesJ Natl Compr Canc Netw20075SupplS1S2917624289
   PubMedGoogle Scholar
• DeMatteoRPMakiRGSingerSResults of tyrosine kinase inhibitor therapy followed by surgical resection in metastatic gastrointestinal stromal tumorAnn Surg200724534735217435539
   PubMed Web of Science ®Google Scholar
• BenjaminRSChoiHMacapinlacHAWe should desist in using RECIST, at least in GISTJ Clin Oncol2009251760176417470866
   PubMed Web of Science ®Google Scholar
• AndtbackaRHNgCHScaifeCLSurgical resection of gastrointestinal tumors after treatment with imatinibAnn Surg Oncol200714142417072676
   PubMed Web of Science ®Google Scholar
• GutierrezJCPerezEAMoffatFLShould soft tissue sarcomas be treated at high volume centers? An analysis of 4205 patientsAnn Surg200724595295817522521
   PubMed Web of Science ®Google Scholar
• BlayJYLeCesneARay-CloquardIProspective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma groupJ Clin Oncol2007251107111317369574
   PubMed Web of Science ®Google Scholar
• RautCPPosnerMDesaiJSurgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitorsJ Clin Oncol2006242325233116710031
   PubMed Web of Science ®Google Scholar
• GronchiAFioreMMiselliFSurgery of residual disease using molecular-targeted therapy with imatinib mesylate in advanced/metastatic GISTAnn Surg2007245245346
   Web of Science ®Google Scholar
• RutkowskiPNoweckiZNyckowskiPSurgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylateJ Surg Oncol20069330431116496358
   PubMed Web of Science ®Google Scholar
• MaeharaNChijiiwaKEtoTSurgical treatment for gastric GIST with special reference to liver metastasesHepatogastroenterology20085551251618613398
   PubMedGoogle Scholar
• JudsonIRPrognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotypeJ Clin Oncol2008265322532518955449
   PubMed Web of Science ®Google Scholar
• BraconiCBracciRCellerinoRMolecular targets in Gastrointestinal Stromal Tumors (GIST) therapyCurr Cancer Drug Targets2008835936618690842
   PubMed Web of Science ®Google Scholar
• DewaeleBWasagBCoolsJActivity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutationClin Cancer Res200815;145749575818794084
   PubMed Web of Science ®Google Scholar
• KitamuraYGastrointestinal stromal tumors: past, present, and futureJ Gastroenterol200843488508
   Web of Science ®Google Scholar
• ReichertPNovel approaches to imatinib-resistant GISTCurr Oncol Rep20081034434918778561
   PubMed Web of Science ®Google Scholar
• HeinrichMCCorlessCLLieglBMechanisms of sunitinib malate resistance in gastrointestinal stromal tumorsProceedings of the American Society for Clinical Oncology20072518S10006(Abstract), 656(S).
   Google Scholar
• ReddyPBociKCharbonneauCThe epidemiologic, health-related quality of life, and economic burden of gastrointestinal stromal tumoursJ Clin Pharm Ther20073255756518021332
   PubMed Web of Science ®Google Scholar